Spinal Cord Injury PSA
Jhalil King Victoria White Nya Paul.

By: Dozier Libbey Health Science 3

Go here to see the original:
Spinal Cord Injury PSA - Video

Recommendation and review posted by sam

19. Spinal Cord Injury (C4/5)Taking Stem Cell Treatment (After)
Patient #39;s name is Mr. Liu, male, 45 years old. In 2000, he got C4/5 fracture falling down from twice floor. After emergency surgery, be become bed ridden. In...

By: Cells Center China

View original post here:
19. Spinal Cord Injury (C4/5)Taking Stem Cell Treatment (After) - Video

Recommendation and review posted by sam

Human Lung Made In Lab For First Time
Human Lung Made In Lab For First Time For the first time, scientists have created human lungs in a lab -- an exciting step forward in regenerative medicine, ...

By: D.A. Beats

Read the rest here:
Human Lung Made In Lab For First Time - Video

Recommendation and review posted by sam

by GEORGE RIBA

WFAA Sports

Posted on February 15, 2014 at 10:35 AM

DALLAS Malena Brown is hoping for a match on this Valentines Day weekend, but its not the kind of match you expect.

The 15-year-old daughter of Dallas Cowboys running backs coach Gary Brown is looking for an "angel donor" whose bone marrow stem cells will match hers and help her overcome what's known as CML, or chronic myeloid leukemia.

Well, its kind of scary knowing that there wasn't a match for me, but we're doing a bone marrow drive now and hopefully find somebody that matches me, Malena said.

Neither one of Malena's siblings is a match, and trying to find one has become a challenge.

The No. 1 challenge has been trying to find a match based on her ancestry, and she being biracial, has been extra difficult because the registry is under-represented with African-American and other multiracial people, said Kim Brown, Malenas mother.

We've had nothing but people trying to help us in any way they can, said father Gary Brown. When you know your daughter is going through something hard, and there are other people out there that care as much as you do and want to help her as much as you do.

To add your name to the national registry, all you do is a simple swab test, add it to a booklet, and send it in.

More:
Cowboys coach seeks marrow match for teen daughter

Recommendation and review posted by Bethany Smith

by GEORGE RIBA

WFAA Sports

Posted on February 14, 2014 at 10:36 PM

Updated today at 8:20 AM

DALLAS Malena Brown is hoping for a match on this Valentines Day weekend, but its not the kind of match you expect.

The 15-year-old daughter of Dallas Cowboys running backs coach Gary Brown is looking for an "angel donor" whose bone marrow stem cells will match hers and help her overcome what's known as CML, or chronic myeloid leukemia.

Well, its kind of scary knowing that there wasn't a match for me, but we're doing a bone marrow drive now and hopefully find somebody that matches me, Malena said.

Neither one of Malena's siblings is a match, and trying to find one has become a challenge.

The No. 1 challenge has been trying to find a match based on her ancestry, and she being biracial, has been extra difficult because the registry is under-represented with African-American and other multiracial people, said Kim Brown, Malenas mother.

We've had nothing but people trying to help us in any way they can, said dad Gary Brown. When you know your daughter is going through something hard, and there are other people out there that care as much as you do and want to help her as much as you do.

See original here:
Cowboys coach seeks marrow match for ailing teen daughter

Recommendation and review posted by Bethany Smith

Blood cell therapy developed
http://www.ktvu.com/videos/news/blood-cell-therapy-developed-for-wounds-that-wont/v576C/ Injuries generally recover normally, the body beginning it #39;s close o...

By: Mundo

See the original post:
Blood cell therapy developed - Video

Recommendation and review posted by Bethany Smith

Weapon X is a fictional clandestine government genetic research facility project in Marvel Comics. They are conducted by the Canadian Government's Department K, which turns willing and unwilling beings into living weapons. The project often captures mutants and experiments on them to enhance their superpowers, turning them into weapons. They also mutate baseline humans. The Weapon X Project produced Wolverine, Leech, and other characters such as Deadpool and Sabretooth.

Experiment X, or the brutal adamantium-skeletal bonding process, written by Barry Windsor-Smith in his classic story "Weapon X" (originally published in Marvel Comics Presents #72-84 in 1991), was eventually revealed as part of the "Weapon X Project." Grant Morrison's run on New X-Men in 2002 further revealed that Weapon X was only the tenth of an entire series of such projects, collectively known as the Weapon Plus Program, and the X in "Weapon X" referred not (or not exclusively) to the letter X, but to the Roman numeral for the number 10. The first project, Weapon I, pertained to the Super Soldier Project that created Captain America.

The code-name Weapon X was first mentioned in the first appearance of Wolverine in The Incredible Hulk #180, in 1974, since which, it had been implied that he was connected to a shady and malevolent government program. In the 1991 Marvel Comics Presents story arc Weapon X, the project was designated Experiment X, and it was revealed that it was responsible for bonding the adamantium to Wolverine's skeleton, making him indestructible. It also subjected him to brainwashing in order to bring out his most basic murderous instincts and to transform him into the perfect assassin. The scientists christened their new killing machine "Weapon X".

Wolverine's solo series issues #48-50 (1992) revealed that Project X also created fabricated memories in the minds of several of its subjects.

Weapon X operated through Canada's Department K and was directed by Professor Andre Thorton. At his side were Dr. Abraham Cornelius, Dr. Carol Hines, and Dr. Dale Rice. John Sublime, the director of Weapon Plus, was always behind the scenes. Some of the work of Weapon X was based on the experiments detailed on the journals of Nazi scientist Nathan Essex, which were obtained by Weapon Plus after the end of World War II.

The project's original test subjects were the members of Team X, a covert ops CIA team (consisting of Wolverine/Logan, Sabretooth/Victor Creed, Maverick/Christoph Nord, Silver Fox, Mastodon, Major Arthur Barrington, Vole/Aldo Ferro, Wildcat/Noel Higgins and Kestrel/John Wraith). The telepath Psi-Borg (Aldo Ferro) was involved in the creation of the victims' memory implants, in exchange for being endowed with immortality. The test subjects were policed by an adaptive robot enforcer, called Shiva, should any of the agents go rogue.

What Wolverine and his fellow X-Men ignored for many years is that Weapon X was part of a larger program called Weapon Plus, a United States super-soldier program created in the 1940s with the purpose of creating super-soldiers and assassins not only to be employed in conventional wars, but also to be employed for the extermination of mutants. Weapon X was the first iteration in Weapon Plus that victimized mutants.

What the Weapon X scientists did not foresee is that the experimentation on Wolverine would cause him to go on a murderous rampage, which allowed the escape of the other test subjects, and caused the death of Dale Rice, among dozens of other members of Weapon X staff, both scientists and military.

Weapon X was temporarily shut down, but eventually was reinstated. Subsequent attempts at recreating the success seen by Weapon X with Wolverine include Native, Kimura and X-23 (the 23rd attempt to clone Wolverine who was designed to also hunt down rogue agents). The Weapon X Re-Creation Project a.k.a. The Facility was headed by Director Martin Sutter, Dr. Zander Rice and Dr. Sarah Kinney. Like Weapon X once did, the Facility has also branched off from the main Weapon X Program. Latter creations of The Facility, now under the direction of Dr. Adam Harkins, include Predator X.

At some point, Weapon X branched off from Weapon Plus' control and was solely headed up by Canada's Department K. A new generation of agents were created: Deadpool, Garrison Kane (who took on the moniker "Weapon X"), Slayback, Sluggo, Wyre, Wildchild, and Ajax, among others. Weapon X used Logan's DNA in order to endow its agents with healing powers. The batch produced many additional failures, which were sent to a facility for dissection to determine the cause of their failures. These rejects were freed by Deadpool when he escaped from the facility.

Read more:
Weapon X - Wikipedia, the free encyclopedia

Recommendation and review posted by Bethany Smith

Spinach looks nothing like parsley, and basil bears no resemblance to thyme. Each plant has a typical leaf shape that can differ even within the same family. The information about what shape leaves will be is stored in the DNA. According to researchers at the Max Planck Institute for Plant Breeding Research in Cologne, the hairy bittercress (Cardamine hirsuta) has a particular gene to thank for its dissected leaves. This homeobox gene inhibits cell proliferation and growth between leaflets, allowing them to separate from each other. The thale cress Arabidopsis thaliana does not have this gene. Therefore, its leaves are not dissected, but simple and entire.

Miltos Tsiantis and his colleagues at the Max Planck Institute for Plant Breeding Research in Cologne discovered the new gene when comparing two plants from the Brassicaceae family: Cardamine hirsuta has dissected leaves that form leaflets and Arabidopsis thaliana has simple leaves. The researchers identified the RCO (REDUCED COMPLEXITY) gene, which makes leaves of the hairy bittercress more complex. Arabidopsis lacks this gene and, accordingly, lacks leaflets. RCO is only active in growing leaves. RCO ensures that cell proliferation and growth is prevented in areas of the leaf margin between sites of leaflet formation. "The leaves of Arabidopsis are simple and entire because growth is not inhibited by the RCO gene," explains Tsiantis. "If we had not compared the two plants we would never have discovered this difference, as it is impossible to find a gene where none exists," he adds.

The scientists first identified the RCO gene through a mutation in the hairy bittercress. In the absence of functional RCO the hairy bittercress can no longer produces leaflets. The RCO gene belongs to a cluster of three genes, which arose during evolution through the duplication of a single gene. In the thale cress, the original triple cluster now consists of a single gene. When the scientists return the RCO gene to the thale cress in the laboratory, evolution is partially reversed. "The simple oval leaves of Arabidopsis now develop deep lobes" says Tsiantis, "The fact that the leaf shape becomes complex again through the transfer of the RCO gene alone, shows that most of the apparatus for the formation of leaflets must still be present in the thale cress and was not lost with the RCO gene."

The research team also examined the RCO sequence in greater detail and found it is a Homeobox gene. These genes function like genetic switches in that they activate or deactivate other genes. The scientists also demonstrated that RCO function is restricted to leaf shape; it does not decide whether leaves actually form. The loss of the RCO gene does not give rise to any other visible changes in the hairy bittercress. Therefore, its effect is limited to the inhibition of growth on the leaf margin. RCO does not work with the plant hormone auxin here. This specificity makes RCO a more likely driver of leaf shape evolution than any other genes identified to date. Tsiantis and his colleagues aim to decode its exact functionality in the months to come.

The scientists also examined the two genes which form a cluster with RCO and which arose in the course of evolution through the duplication of a precursor gene. They wanted to find out how the novel function of RCO in promoting leaf complexity arose. Apparently, the main functional difference lies in the control regions of the genes and not in the protein sequences. The control regions dictate when and how the relevant gene is read. If one or other of the two genes is subjected to the effect of the RCO control region, Arabidopsis makes complex leaves. Thus, the dissected leaves of the hairy bittercress are primarily owed to the control region of the RCO gene.

Story Source:

The above story is based on materials provided by Max-Planck-Gesellschaft. Note: Materials may be edited for content and length.

More here:
Gene for dissected leaves: Lost gene leads to simple leaves

Recommendation and review posted by Bethany Smith

Ask A CTA!
As the midterm rapidly approaches, join a panel of CTAs as they answer your questions on materials from Weeks 1-5. Questions can be left in the Discussion F...

By: Introduction to Genetics and Evolution Coursera

View post:
Ask A CTA! - Video

Recommendation and review posted by Bethany Smith

Genetics and DNA
Genetics is a study of changes in physical traits over time. Kawan ng Cordero is the only Bible-based kiddie show on television. It stirs the interest of the...

By: untvweb

Excerpt from:
Genetics and DNA - Video

Recommendation and review posted by Bethany Smith

My Biggest Dab So Far - Lady Sativa Genetics Knightsbridge OG BHO (Amsterdam Weed Review)
http://andrew.pyrah.net Thanks for watching! COMMENT and LIKE if you enjoyed the video and SUBSCRIBE to see my new videos as they are released. This video is...

By: Andrew Pyrah

Here is the original post:
My Biggest Dab So Far - Lady Sativa Genetics Knightsbridge OG BHO (Amsterdam Weed Review) - Video

Recommendation and review posted by Bethany Smith

By Callum Borchers/Globe Staff/February 12, 2014

A Cambridge biotechnology company launching Wednesday is taking aim at Parkinsons disease and ALS with a new gene therapy that deliberately infects patients with a virus.

The firm, Voyager Therapeutics, plans to use a class of viruses known as adeno-associated viruses as carriers to deliver vital proteins to the brain. Intentional infection may be counterintuitive, but the viruses used in the therapy are harmless to humans, making them ideal vehicles for moving proteins throughout the body, without troublesome side effects.

Boston venture capital firm Third Rock Ventures considered Voyagers research so promising that it invested $45 million to get the company off the ground, an unusually big bet on such an early stage life sciences firm.

Were just convinced that these viruses are going to be incredibly important delivery vehicles to different parts of the body and make a big difference in a lot of very serious disorders, said Third Rock cofounder Mark Levin, who will serve as Voyagers interim chief executive during the companys start-up phase.

The investment in Voyager marks Third Rocks latest foray into genetic medicine and the treatment of rare diseases. Bluebird bio of Cambridge, another gene therapy company in its portfolio, raised more than $100 million in an initial public stock offering last June. Bluebird is working on a treatment to slow the progression of a genetic brain disorder called childhood cerebral adrenoleukodystrophy, or CCALD.

In November, Third Rock joined two other venture firms in putting a combined $43 million behind a Cambridge start-up called Editas Medicine, which is developing a technique to edit faulty genes, such as those that cause Huntingtons disease and sickle cell anemia.

The investments reflect a broader belief among the scientific community that gene therapy could be the key to effectively treating some of the worlds most challenging disorders. Gene therapy techniques typically involve replacing a mutated gene with a healthy version or turning off a gene that causes disease.

Voyager plans to use adeno-associated viruses as carriers for both techniques. To treat Parkinsons, for instance, Voyager will use viruses to deliver a missing protein. For ALS, the viruses will help shut down a harmful protein.

Expecting gene therapy to produce cures for rare diseases might be unrealistic, Levin said, but the idea is to make a dramatic difference in patients lives.

See the article here:
Biotech start-up Voyager Therapeutics uses new gene therapy to attack diseases - Boston.com

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

13-Feb-2014

Contact: Joseph Caputo joseph_caputo@harvard.edu 617-496-1491 Harvard University

Harvard stem cell scientists have a new theory for how stem cells decide whether to become liver or pancreatic cells during development. A cell's fate, the researchers found, is determined by the nearby presence of prostaglandin E2, a messenger molecule best known for its role in inflammation and pain. The discovery, published in the journal Developmental Cell, could potentially make liver and pancreas cells easier to generate both in the lab and for future cell therapies.

Wolfram Goessling, MD, PhD, and Trista North, PhD, both principal faculty members of the Harvard Stem Cell Institute (HSCI), identified a gradient of prostaglandin E2 in the region of zebrafish embryos where stem cells differentiate into the internal organs. Experiments conducted by postdoctoral fellow Sahar Nissim, MD, PhD, in the Goessling lab showed how liver-or-pancreas-fated stem cells have specific receptors on their membranes to detect the amount of prostaglandin E2 hormone present and coerce the cell into differentiating into a specific organ type.

"Cells that see more prostaglandin become liver and the cells that see less prostaglandin become pancreas," said Goessling, a Harvard Medical School Assistant Professor of Medicine at Brigham and Women's Hospital and Dana-Farber Cancer Institute. "This is the first time that prostaglandin is being reported as a factor that can lead this fate switch and essentially instruct what kind of identity a cell is going to be."

The researchers next collaborated with the laboratory of HSCI Affiliated Faculty member Richard Maas, MD, PhD, Director of the Genetics Division at Brigham and Women's Hospital, to see whether prostaglandin E2 has a similar function in mammals. Richard Sherwood, PhD, a former graduate student of HSCI Co-director Doug Melton, was successfully able to instruct mouse stem cells to become either liver or pancreas cells by exposing them to different amounts of the hormone. Other experiments showed that prostaglandin E2 could also enhance liver growth and regeneration of liver cells.

Goessling and his research partner North, a Harvard Medical School Assistant Professor of Pathology at Beth Israel Deaconess Hospital, first became intrigued by prostaglandin E2 in 2005, as postdoctoral fellows in the lab of HSCI Executive Committee Chair Leonard Zon, MD. It caught their attention during a chemical screen exposing 2,500 known drugs to zebrafish embryos to find any that could amplify blood stem cell populations. Prostaglandin E2 was the most successful hit the first molecule discovered in any system to have such an effectand recently successfully completed Phase 1b clinical trials as a therapeutic to improve cord blood transplants.

"Prostaglandin might be a master regulator of cell growth in different organs," Goessling said. "It's used in cord blood, as we have shown, it works in the liver, and who knows what other organs might be affected by it."

With evidence of how prostaglandin E2 works in the liver, the researchers next want to calibrate how it can be used in the laboratory to instruct induced pluripotent stem cellsmature cells that have been reprogrammed into a stem-like stateto become liver or pancreas cells. The scientists predict that such a protocol could benefit patients who need liver cells for transplantation or who have had organ injury.

Visit link:
Harvard scientists find cell fate switch that decides liver, or pancreas?

Recommendation and review posted by simmons

Instead of being shut out of a $40 million stem cell grant awarded to Stanford University, San Diego researchers will be major partners, say the scientists who lead the project.

Joseph Ecker of the Salk Institute and Michael Snyder of Stanford say that under an informal arrangement, they will jointly allocate money granted from the California Institute for Regenerative Medicine for a new center on stem cell genomics. CIRM is responsible for distributing $3 billion in state bond money to turn stem cell research into disease treatments.

Joseph Ecker, a Salk Institute researcher and co-principal investigator of the new center for stem cell genomics created with a $40 million grant from the California Institute for Regenerative Medicine. / Salk Institute

Genomics, the study of the complete set of genes and DNA in an organism, is necessary to help understand how stem cells function. Stem cells contain virtually the same genes as adult cells but differ in which genes are turned on and off. The signals that cause stem cells to differentiate are not well understood.

By analyzing the genomes of stem cells, researchers expect to better understand how stem cells can produce more stem cells, and which genes are involved in directing stem cells down the path to becoming adult cells of interest, such as islet cells that make insulin, bone or retinal cells.

Last months decision had been characterized as a big win for Stanford, because the university had been awarded the grant over competing applications, including one from The Scripps Research Institute and San Diego DNA sequencing giant Illumina.

Ecker and Snyder said that belief is a misunderstanding, because their proposal is a cooperative venture involving extensive participation from San Diego biomedical scientists.

Michael Snyder, a Stanford University researcher and co-principal investigator of the new center for stem cell genomics created with a $40 million grant from the California Institute for Regenerative Medicine. / Stanford University

The leadership issue is confusing, because CIRM requires a single institute to be listed as the lead on funding proposals, even if the institutions are sharing leadership, Ecker said by email. In fact, Mike Snyder and I, by proxy Stanford and Salk, are equal partners. Responsibility for administration of the center will fall equally to Stanford and Salk researchers, as well as strategic steering and decision-making on what projects to pursue.

Besides Salk and Stanford, partners are UC San Diego, the Ludwig Institute for Cancer Research, the J. Craig Venter Institute, The Scripps Research Institute and UC Santa Cruz. The Howard Hughes Medical Institute also plays a role.

More:
Salk, Stanford equal partners in stem cell genomics program

Recommendation and review posted by simmons

How will Big Data facilitate Personalized Medicine?
Oracle Health Sciences Dave Watson, VP Product Strategy discusses the implications of big data and personalized medicine.

By: OracleHealthSciences

Read more:
How will Big Data facilitate Personalized Medicine? - Video

Recommendation and review posted by sam

Patient Participation in Personalized Medicine
How do patients participate in this new personalized medicine?

By: OracleHealthSciences

Read the original post:
Patient Participation in Personalized Medicine - Video

Recommendation and review posted by sam

Personalized Medicine - the Doctor-Patient Relationship
How does the role of the doctor-patient relationship change with personalized medicine?

By: OracleHealthSciences

See the original post here:
Personalized Medicine - the Doctor-Patient Relationship - Video

Recommendation and review posted by sam

10. Spinal Cord Injury (L1)with stem cell treatment (before)
Name: Wu Age: 22 Diagnosis: Spinal Cord Injury (L1) Wu got L1 damage on 9th, June 2011 when he was 22 years old. After emergent surgery, he started rehabilit...

By: Cells Center China

More here:
10. Spinal Cord Injury (L1)with stem cell treatment (before) - Video

Recommendation and review posted by sam

10. Spinal Cord Injury (L1)with stem cell treatment(after)
Name: Wu Age: 22 Diagnosis: Spinal Cord Injury (L1) Wu got L1 damage on 9th, June 2011 when he was 22 years old. After emergent surgery, he started rehabilit...

By: Cells Center China

View post:
10. Spinal Cord Injury (L1)with stem cell treatment(after) - Video

Recommendation and review posted by sam

natalie on tg
using the total gym to achieve weight bearing to activate legs.

By: ProjectWalkAtlanta Spinal Cord Injury Recovery

View post:
natalie on tg - Video

Recommendation and review posted by sam

Spinal Cord Injury "Little Things"
I #39;ve been paralyzed for a little over 8 months at this point and just wanted to put together a little video of some of the little things I face everyday. I d...

By: Yvonne Michaud

Read the original here:
Spinal Cord Injury "Little Things" - Video

Recommendation and review posted by sam

Jess-Training Hard
Jess spends hours training for her races. She has a roller at FSWC that allows her to train after her therapy sessions or any day of the week. Dedication, ha...

By: First Steps Wellness Centre

The rest is here:
Jess-Training Hard - Video

Recommendation and review posted by sam

Regenerative medicine for complex abdominal wall reconstruction
Presented by Scott T. Rehrig, MD.

By: Surgery Videos from SAGES

Read more:
Regenerative medicine for complex abdominal wall reconstruction - Video

Recommendation and review posted by sam

Total Recovery Lecture Series: Novel Treatments for Joint, Tendon Ligament Pain: Part 1

By: KaplanCenter

Read this article:
Total Recovery Lecture Series: Novel Treatments for Joint, Tendon & Ligament Pain: Part 1 - Video

Recommendation and review posted by sam

Utilizing B cells to recreate the biochemical environment of youth - Matthew Scholz
New proteins that affect or play a role in aging are continually being discovered. While some of these molecules may have great potential for reversing aging...

By: SENS Foundation

Original post:
Utilizing B cells to recreate the biochemical environment of youth - Matthew Scholz - Video

Recommendation and review posted by sam